What is the 13F Pro Quality Score for GERN?

13F Pro ranks GERON CORP (GERN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GERN's current score at https://13fpro.ai/company/GERN (free sign-up required for the full ranking).

Where does 13F Pro source GERN data?

All GERON CORP fundamentals and ownership data come directly from SEC EDGAR. GERON CORP files with the SEC under CIK 886744. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GERN in?

GERON CORP (GERN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GERN research updated on 13F Pro?

GERN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GERON CORP(GERN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 886744 GERN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

GERN Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for GERON CORP (GERN), a Healthcare sector company. GERN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), GERON CORP reports quarterly revenue of $57.5M, net income of $-16.7M, an operating margin of -21.7%. Top institutional holders of GERN by reported 13-F value include BlackRock, RA CAPITAL MANAGEMENT, L.P., Soleus Capital Management, L.P., based on the most recent SEC filings. GERN trades on the Nasdaq exchange and files with the SEC under CIK 886744. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GERN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GERON CORP directly from SEC EDGAR. GERON CORP's 13F Pro composite quality score has ranged between 14 and 35 since 2024, currently 35.4 — an improving long-term trajectory across 9 quarterly and live scoring snapshots.

✦

Fun facts about GERON CORP

Quirks, history, and lore behind GERN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. clinical-stage biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in California.
2
The Numbers
Minimal product revenue for most of its history — a company that has operated at a net loss for decades while burning through hundreds of millions in R&D funding.
3
The History
Founded in the 1990s, it spent over two decades in clinical trials pursuing one of the most scientifically ambitious targets in oncology: stopping cancer cells from cheating death.
4
The Secret
Its entire pipeline is built around telomerase inhibition — targeting the enzyme that lets cancer cells replicate forever, a mechanism most drugmakers abandoned as too hard.
5
The Lore
Its lead drug imetelstat took so long to reach approval that it became something of a legend among biotech bears and believers alike — a decades-long trial of investor patience.
6
The Giveaway
In 2024, the FDA approved imetelstat for low-risk myelodysplastic syndromes — ending a 30-year quest to bring the world's first telomerase inhibitor to market.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$57.5M

Net Income

Q2 2026

$-16.7M

Operating Margin

Q2 2026

-21.7%

ROIC

Q2 2026

-14.8%

D/E Ratio

Q2 2026

0.55

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $596.0KFY23 $237.0KFY24 —FY25 —

Net Income

+52.2% YoY

$-83.5MFY 2025

FY22 $-141.9MFY23 $-184.1MFY24 $-174.6MFY25 $-83.5M

Operating Income

+60.5% YoY

$-68.6MFY 2025

FY22 $-138.6MFY23 $-193.9MFY24 $-173.7MFY25 $-68.6M

EPS (Diluted)

+51.9% YoY

$-0.13FY 2025

FY22 $-0.37FY23 $-0.32FY24 $-0.27FY25 $-0.13

Total Assets

-3.9% YoY

$570.5MFY 2025

FY22 $190.6MFY23 $394.1MFY24 $593.8MFY25 $570.5M

Total Debt

+0.9% YoY

$119.5MFY 2025

FY22 $72.1MFY23 $128.8MFY24 $118.5MFY25 $119.5M

Op. Cash Flow

+49.2% YoY

$-111.0MFY 2025

FY22 $-127.4MFY23 $-167.7MFY24 $-218.6MFY25 $-111.0M

Free Cash Flow

—FY 2025

FY22 $-127.8MFY23 $-168.6MFY24 $-219.3MFY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	$237.0K -60.2%	$596.0K -57.2%	$1.4M +450.6%	$253.0K
Net Income	$-83.5M +52.2%	$-174.6M +5.2%	$-184.1M -29.8%	$-141.9M -22.2%	$-116.1M -53.6%	$-75.6M
Operating Income	$-68.6M +60.5%	$-173.7M +10.4%	$-193.9M -40.0%	$-138.6M -21.5%	$-114.0M -48.2%	$-76.9M
EPS (Diluted)	$-0.13 +51.9%	$-0.27 +15.6%	$-0.32 +13.5%	$-0.37 -5.7%	$-0.35 -25.0%	$-0.28
Total Assets	$570.5M -3.9%	$593.8M +50.7%	$394.1M +106.8%	$190.6M -15.7%	$226.0M -16.5%	$270.7M
Total Debt	$119.5M +0.9%	$118.5M -8.0%	$128.8M +78.7%	$72.1M +44.7%	$49.8M +107.3%	$24.0M
Operating Cash Flow	$-111.0M +49.2%	$-218.6M -30.3%	$-167.7M -31.7%	$-127.4M -33.3%	$-95.6M -43.4%	$-66.7M
Free Cash Flow	—	$-219.3M -30.1%	$-168.6M -31.9%	$-127.8M -33.5%	$-95.8M -42.8%	$-67.1M

Get alerted when GERN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GERON CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GERN

BlackRock, Inc.
$62.9M49,115,571 sh
RA CAPITAL MANAGEMENT, L.P.
$54.8M42,809,751 sh
Soleus Capital Management, L.P.
$54.8M42,808,659 sh
STATE STREET CORP
$45.9M35,856,671 sh
CITADEL ADVISORS LLC
$37.2M29,038,928 sh
VANGUARD CAPITAL MANAGEMENT LLC
$34.9M27,250,215 sh
Clearbridge Investments, LLC
$25.2M19,648,853 sh
Eversept Partners, LP
$24.0M18,717,422 sh
GOLDMAN SACHS GROUP INC
$21.3M16,633,368 sh
GEODE CAPITAL MANAGEMENT, LLC
$18.6M14,555,954 sh

Fund	Value	Shares
BlackRock, Inc.	$62.9M	49,115,571
RA CAPITAL MANAGEMENT, L.P.	$54.8M	42,809,751
Soleus Capital Management, L.P.	$54.8M	42,808,659
STATE STREET CORP	$45.9M	35,856,671
CITADEL ADVISORS LLC	$37.2M	29,038,928
VANGUARD CAPITAL MANAGEMENT LLC	$34.9M	27,250,215
Clearbridge Investments, LLC	$25.2M	19,648,853
Eversept Partners, LP	$24.0M	18,717,422
GOLDMAN SACHS GROUP INC	$21.3M	16,633,368
GEODE CAPITAL MANAGEMENT, LLC	$18.6M	14,555,954

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GERN on your watchlist

Track score changes the day GERON CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GERN a good stock to buy?

13F Pro's AI-powered analysis of GERON CORP (GERN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GERN are available on the GERN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GERN is classified as a small company.

Which hedge funds own GERN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GERN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GERON CORP's investment landscape.